/ /

Michelle Dalton
New tool to evaluate dark adaptation
Almost 70% of patients with age-related macular degeneration (AMD) are unaware of their disease until vision loss has occurred, said Gregory R. Jackson, PhD.
Using suprachoroidal drug delivery
Local delivery of pharmacotherapy to the eye has long been used for anterior segment disease, but various routes for delivery have also been investigated, said Timothy Olsen, MD.
NSAIDs offer potential hope for DR, AMD
Nonsteroidal anti-inflammatory drugs (NSAIDs) are well recognized as potent agents as they block all downstream prostaglandins, have a long history of safety and efficacy, and fare well in extended-release formulations. Recently, there has been a growing body of evidence showing they have potential in treating cystoid macular edema, said Stephen Kim, MD.
Genes identify potential risk for AMD
Patients with 2 CFH risk alleles and no ARMS2 risk alleles would be better served by not taking the Age-Related Eye Disease Study (AREDS) formulation, according to Carl C. Awh, MD.
Cataract surgery costs, complications low at Aravind
Due to the extraordinarily high volume and minimal surgeon time, the average cataract cost—including IOL choice—ranges from $41 to $125 at India’s Aravind Eye Hospital, said David W. Hutton.
Accommodative lens outcomes less than stellar
An evaluation of four randomized clinical trials found no evidence to recommend the use of accommodative IOLs, said Hon Shing Ong, MBBS.
Long-term stability of ranibizumab shown in DME patients
In roughly 25% of patients, no further treatment was required to maintain mean visual acuity (VA) outcomes achieved at the exit of the RIDE/RISE 3-year core studies evaluating the efficacy of ranibizumab in patients with diabetic macular edema (DME), according to Allen Ho, MD.
IOP more dynamic than previously thought
The typical eye undergoes 12,000 intraocular pressure (IOP) spikes per hour while awake, and about 3,000 spikes per hour when sleeping, according to J. Crawford Downs.
Photodynamic therapy and chronic CSC
Photodynamic therapy has been found to reduce subretinal fluid and increase visual acuity for patients with central serous chorioretinopathy.
Combined steroids, anti-VEGFs show promise in DME
For some patients with diabetic macular edema, treatment with anti-vascular endothelial growth factor agents may not be enough. Clinicians need to consider other options, including dexamethasone implants.


View Results